Clinical Trials

100 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05972135 2026-02-23

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

100 enrolled

Cytokine Release Syndrome, Multiple Myeloma

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Phase 2 Completed

15 enrolled 17 charts

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT06421675 2025-11-14

EMBRACE

40 enrolled

Phase 2 Active not recruiting

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT04975555 2025-09-22

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

30 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

20 enrolled

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2 Withdrawn

Cytokine Release Syndrome, Multiple Myeloma

NCT04466098 2025-01-29

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Phase 2 Completed

8 enrolled 21 charts

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Respiratory Distress Syndrome

NCT04358406 2023-11-28

Rhu-pGSN for Severe Covid-19 Pneumonia

Phase 2 Completed

64 enrolled 17 charts